Avagacestat: Development discontinued

Bristol-Myers discontinued development of avagacestat after data from a pair of Phase II trials in patients with mild to moderate AD and predementia AD, respectively, did not "establish a profile that supported advancement" to Phase III testing. The pharma plans to present data from the Phase II CN156-018 predementia trial next year, while data from the Phase II CN156-013 trial in mild to moderate AD were reported last year (see BioCentury, July 25, 2011). ...